Endoxifen – (110025-28-0)

Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) and a protein kinase C (PKC) inhibitor.

It is an active metabolite of tamoxifen and is under development for the treatment of estrogen receptor-positive breast cancer and mania in bipolar disorder. It is metabolized from tamoxifen by the CYP2D6 enzyme.

Endoxifen exhibits both estrogenic and antiestrogenic actions and has a higher affinity for estrogen receptors compared to tamoxifen. It is also being investigated for its potential in breast cancer treatment.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Endoxifen
https://www.medchemexpress.com/Endoxifen.html
https://www.medkoo.com/products/12944
https://pmc.ncbi.nlm.nih.gov/articles/PMC8787422/